We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

137 hedge funds and large institutions have $1.41B invested in Lexicon Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 33

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

1% more funds holding

Funds holding: 135 → 137 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.4% less ownership

Funds ownership: 109.14% → 108.74% (-0.4%)

25% less capital invested

Capital invested by funds: $1.89B → $1.41B (-$478M)

88% less call options, than puts

Call options by funds: $1.77M | Put options by funds: $14.2M

Holders
137
Holders Change
+2
Holders Change %
+1.48%
% of All Funds
3.42%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
44
Reduced
33
Closed
20
Calls
$1.77M
Puts
$14.2M
Net Calls
-$12.4M
Net Calls Change
-$26.6M

Top Buyers

1
KCM
Kornitzer Capital Management
Kansas
+$11.3M
2
Bank of America
Bank of America
North Carolina
+$6.06M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$5.18M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$4.15M
5
PA
Pinnacle Associates
New York
+$2.69M

Top Sellers

1
Norges Bank
Norges Bank
Norway
-$12.5M
2
KCM
Kingdon Capital Management
New York
-$7.96M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$5.61M
4
Millennium Management
Millennium Management
New York
-$4.56M
5
CCI
Columbus Circle Investors
-$3.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$3.54M -$1.42M -96,011 -25%
Norges Bank
27
Norges Bank
Norway
$3.27M -$12.5M -844,843 -76%
Goldman Sachs
28
Goldman Sachs
New York
$3M +$1.63M +110,293 +82%
Charles Schwab
29
Charles Schwab
California
$2.51M +$160K +10,811 +6%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.5M -$779K -52,755 -21%
AllianceBernstein
31
AllianceBernstein
Tennessee
$2.23M +$1.48M +100,000 +122%
DekaBank Deutsche Girozentrale
32
DekaBank Deutsche Girozentrale
Germany
$2.08M – – –
UBS Group
33
UBS Group
Switzerland
$1.95M +$374K +25,330 +19%
HT
34
HAP Trading
New York
$1.86M +$2.23M +151,078 New
TAM
35
Tocqueville Asset Management
New York
$1.66M +$1.99M +135,000 New
Wellington Management Group
36
Wellington Management Group
Massachusetts
$1.44M +$1.73M +117,255 New
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$1.44M – – –
TCIM
38
TIAA CREF Investment Management
New York
$1.43M +$15.4K +1,041 +0.9%
Wells Fargo
39
Wells Fargo
California
$1.39M +$356K +24,131 +27%
Two Sigma Investments
40
Two Sigma Investments
New York
$1.38M +$397K +26,871 +31%
WS
41
Wedbush Securities
California
$1.38M +$363K +24,593 +28%
JP Morgan Chase
42
JP Morgan Chase
New York
$1.29M -$59.8K -4,052 -4%
Morgan Stanley
43
Morgan Stanley
New York
$1.28M +$481K +32,557 +45%
Stifel Financial
44
Stifel Financial
Missouri
$987K +$130K +8,833 +12%
Swiss National Bank
45
Swiss National Bank
Switzerland
$983K – – –
TA
46
Teachers Advisors
New York
$949K – – –
PAMU
47
Pictet Asset Management (UK)
United Kingdom
$925K +$108K +7,300 +11%
NFA
48
Nationwide Fund Advisors
Ohio
$920K -$28.3K -1,914 -2%
Citigroup
49
Citigroup
New York
$899K +$431K +29,162 +66%
Group One Trading
50
Group One Trading
Illinois
$861K +$1.04M +70,092 New
1
2
3 4 5

LXRX Hedge Fund Activity: Q3 2017 in Review

137 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2017, worth a combined $1.41B — down 25% from $1.89B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LXRX positions and 20 closed out — a net gain of 3 holders — while 44 added to existing stakes and 33 trimmed.

The largest buyer was Kornitzer Capital Management, opening a new position worth an estimated $11.3M. The largest seller was Norges Bank, cutting an estimated $12.5M.

  • 137 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2017, up from 135 in Q2 2017.
  • Funds reported $1.41B of Lexicon Pharmaceuticals stock for Q3 2017, down 25% quarter-over-quarter.
  • 23 funds opened new Lexicon Pharmaceuticals positions in Q3 2017 and 20 closed out, a net change of +3 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q3 2017 was Kornitzer Capital Management, an estimated $11.3M added.
  • The largest Lexicon Pharmaceuticals seller in Q3 2017 was Norges Bank, an estimated $12.5M sold.

Based on aggregated 13F filings for Q3 2017.